<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708370</url>
  </required_header>
  <id_info>
    <org_study_id>A2581162</org_study_id>
    <nct_id>NCT00708370</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.</brief_title>
  <acronym>DISSEMINATE</acronym>
  <official_title>An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a local PCO sponsored, interventional, non-drug study to evaluate the efficacy
      of a health tele-counselling program in reducing cardiovascular risk in dyslipidemic
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Educational / Counseling
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) change from baseline to week 24 in serum LDL-C levels.</measure>
    <time_frame>24 weeks from Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects' lifestyle modification as assessed by the incidence and frequency of smoking, consumption of foods high in salt, sugar and/or fat content, alcohol consumption, and exercise habits at baseline and weeks 24 and 36.</measure>
    <time_frame>24 and 36 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) change from baseline in serum LDL-C (week 36), TC (week 24 and 36), HDL-C (week 24 and 36), TG (week 24 and 36) and TC/HDL-C ratio (week 24 and 36).</measure>
    <time_frame>24 and 36 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' satisfaction with the Health Booklet and the COACH program after 24 weeks.</measure>
    <time_frame>24 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in SBP and DBP from baseline to weeks 24 and 36.</measure>
    <time_frame>24 and 36 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (%) change in Framingham CHD risk score from baseline to weeks 24 and 36.</measure>
    <time_frame>24 and 36 weeks from Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">297</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>COACH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COACH</intervention_name>
    <description>COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.</description>
    <arm_group_label>COACH</arm_group_label>
    <other_name>COACH plus Standard Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention for placebo</intervention_name>
    <description>There will be no COACH health tele-counselling to patients randomized to Standard Care arm.</description>
    <arm_group_label>Standard Care</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are newly diagnosed with dyslipidemias.

          2. Subjects must be lipid drug naive and eligible for statin therapy.

        Exclusion Criteria:

          1. Subjects who cannot be contacted by telephone or handphone.

          2. Subjects with uncontrolled primary hypothyroidism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jitra, Kubang Pasu</city>
        <state>Kedah</state>
        <zip>06200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kulim</city>
        <state>Kedah</state>
        <zip>09400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sik</city>
        <state>Kedah</state>
        <zip>08200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kubang Kerian</city>
        <state>Kelantan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>55300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nilai</city>
        <state>Negeri Sembilan</state>
        <zip>71800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampin</city>
        <state>Negeri Sembilan</state>
        <zip>73000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bagan Serai</city>
        <state>Perak</state>
        <zip>34300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lenggong</city>
        <state>Perak</state>
        <zip>33400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Slim River</city>
        <state>Perak</state>
        <zip>35860</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kapar</city>
        <state>Selangor</state>
        <zip>42200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <zip>46000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Puchong</city>
        <state>Selangor</state>
        <zip>47100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sungai Buloh</city>
        <state>Selangor</state>
        <zip>47000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kemaman</city>
        <state>Terengganu</state>
        <zip>24100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kerteh, Kemaman</city>
        <state>Terengganu</state>
        <zip>24300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>57000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50480</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>52000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melaka</city>
        <zip>75460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shah Alam</city>
        <zip>40460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581162&amp;StudyName=A%20Study%20to%20Evaluate%20the%20Efficacy%20of%20a%20Counselling%20and%20Advisory%20Care%20for%20Health%20%28COACH%29%20Program%20in%20Dyslipidemic%20Patients.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Interventional</keyword>
  <keyword>Non-drug</keyword>
  <keyword>Disease Management Program</keyword>
  <keyword>Cardiovascular Risk Control</keyword>
  <keyword>Dyslipidemias</keyword>
  <keyword>Primary Care Centers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

